熱門資訊> 正文
Travere获得FDA全面批准肾脏药物Filspari
2024-09-06 18:45
- Travere Therapeutics (NASDAQ:TVTX) traded higher in the premarket on Friday after the U.S. Food and Drug Administration (FDA) granted full approval for its kidney disease drug, Filspari (sparsentan).
- The once-daily oral medication developed by Travere (TVTX) in partnership with Ligand Pharmaceuticals (NASDAQ:LGND) was granted the FDA’s accelerated approval in Feb. 2023 to reduce proteinuria in adults with IgA nephropathy, a rare progressive kidney disease.
- While accelerated approval was based on the surrogate marker of proteinuria, long-term confirmatory results from the company’s PROTECT study backed its full approval.
- “Full approval now enables physicians to confidently prescribe FILSPARI more broadly as a once-daily, oral, non-immunosuppressive treatment, that can provide superior preservation of kidney function and replace current standard of care,” said Travere (TVTX) CEO Eric Dube.
More on Ligand Pharmaceuticals, Travere Therapeutics, etc.
- Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
- Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript
- Ligand Pharmaceuticals Incorporated 2024 Q2 - Results - Earnings Call Presentation
- Roth MKM says Small-Cap Value reaches key technical support, lists 14 "bullish" stocks
- Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
